Vidarbha News

Presbyopia Market Insight, Epidemiology and Market Forecast – 2030

 Breaking News
  • No posts were found

Presbyopia Market Insight, Epidemiology and Market Forecast – 2030

August 10
23:37 2021
Presbyopia Market Insight, Epidemiology and Market Forecast - 2030
DelveInsight Business Research LLP
DelveInsight’s ‘Presbyopia Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of Presbyopia, historical and forecasted epidemiology as well as Presbyopia market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Presbyopia Market

The Presbyopia market report provides current treatment practices, emerging drugs, Presbyopia market share of the individual therapies, current and forecasted Presbyopia market size from 2018 to 2030 segmented by seven major markets. The Report also covers current Presbyopia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Presbyopia Epidemiology

The Presbyopia epidemiology division provides insights about historical and current Presbyopia patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Key Findings

In the year 2020, the total prevalent case of Presbyopia was 286,994,105 cases in the 7MM which are expected to grow during the forecast period, i.e., 2021–2030.

 

The disease epidemiology covered in the report provides historical as well as forecasted Presbyopia epidemiology [segmented as Total Prevalent Cases of Presbyopia, Total Diagnosed Cases of Presbyopia, Total Age-specific Cases of Presbyopia, Gender-specific Cases of Presbyopia, Severity-specific Cases of Presbyopia, and Total Treated cases of Presbyopia] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country Wise- Presbyopia Epidemiology

Estimates show that the highest cases of Presbyopia in the 7MM were in the United States, followed by Germany, Japan, Italy, France, the United Kingdom, and Spain in 2020.

  • In the United States, the total number of prevalent cases of Presbyopia was 117,369,699 cases in the year 2020 which are expected to grow during the forecast period, i.e., 2021–2030.
  • In the year 2020, the total prevalent cases of Presbyopia were 134,726,460 cases in EU-5 which are expected to grow during the forecast period, i.e., 2021–2030.
  • In Japan, the total number of prevalent cases of Presbyopia was 34,897,947 cases in the year 2020 which are expected to grow during the forecast period, i.e., 2021–2030.

Presbyopia Drug Chapters

The drug chapter segment of the Presbyopia report encloses the detailed analysis of Presbyopia late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Presbyopia clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

 

Presbyopia Emerging Drugs

 

PresbiDrops/CSF-1 (Orasis Pharmaceuticals)

CSF-1, also known as PresbiDrops, is a corrective eye drop being developed by Orasis Pharmaceuticals to offer an alternative to reading glasses and intrusive surgical procedures to enhance the quality of life for people with presbyopia. CSF-1 is delivered directly to the eyes as a topical solution and provides a patented blend of current and well-studied ingredients with the potential for close vision restoration in people with presbyopia. It is being developed to improve near visual acuity by pupil modulation, resulting in a “pinhole effect” and an increase in the depth of field, thus increasing the ability to focus on near objects. A Phase II clinical trial of CSF-1 showed very high success rates for two-line and three-line improvement, attesting that CSF-1 eliminates the need for reading glasses for many people. Also, CSF-1 had no negative impact on distance vision, night vision, and visual field.

 

MicroLine/Pilocarpine Ophthalmic (Eyenovia)

MicroLine is Eyenovia’s patented pilocarpine presbyopia formulation. Pilocarpine is a well-characterized drug, with several trials showing its ability to improve the depth of focus of the eye to reverse the age-related loss of accommodative effect and enhance close vision. Pilocarpine works by creating a pinhole effect, which is done by constricting the pupil of the eye, similar to a pinhole camera, and bringing near and medium-distance objects into focus. The MicroLine of Eyenovia is a patented micro-dosed pilocarpine formulation distributed through the Optejet dispenser. Currently, the company has initiated a Phase III clinical trial wherein volunteer participants will be evaluated for eligibility during a screening visit. The US FDA has also accepted Eyenovia’s IND application for MicroLine in December 2020 for the improvement in near vision in patients with presbyopia.

 

UNR844/Lipoic acid choline ester (Novartis)

UNR844, formerly known as EV06, is being developed by Novartis as a new topical agent to boost the accommodative spectrum for presbyopia. UNR844 contains lipoic acid choline ester, a decreasing agent intended to decrease the disulfide bonds that form between proteins of the lens, thereby raising the crystalline lens deformability and increasing the accommodative amplitude. Novartis gained possession of this drug in December 2016 with the acquisition of Encore Vision. Currently, UNR844 has completed the Phase II of the clinical developmental stage.

 

AGN-190584 (AbbVie)

AbbVie’s Allergan is developing AGN-190584, an investigational optimized formulation of pilocarpine. It is a cholinergic muscarinic receptor agonist being investigated for treating symptoms associated with presbyopia as a topical, once-daily drop delivered by a proprietary vehicle. The goal of this pupil size reduction is to increase the depth of focus. Secondarily, it is believed to allow for increased accommodation through mild contraction of the ciliary muscle. AGN-190584 for the treatment of symptoms associated with presbyopia met their primary efficacy endpoint in Phase III GEMINI 1 and 2 clinical trials.

 

AGN-241622 (AbbVie)

AGN-241622 is a second investigational drug from AbbVie’s Allergan. It is an Alpha 2 agonist being investigated for the treatment of presbyopia; the drug is a small molecule that targets the Alpha 2 Adrenergic Receptor. AGN-241622 is currently being investigated in Phase I/II of clinical studies, and the study is estimated to be completed in August 2022.

 

Nyxol (Occuphire Pharma)

Nyxol is a preservative-free ophthalmic solution containing 0.75% phentolamine (or 1% phentolamine mesylate), a nonselective alpha-adrenergic antagonist that inhibits the contraction of the smooth muscle of the iris. Nyxol’s potential to improve near vision is based on its mechanism of reducing pupil diameter, which results in an increased depth of focus. It alone has been shown to reduce pupil diameter by approximately 20% and has significantly improved near visual acuity by one eye-chart line for over 24 h after an evening eye drop. It is being developed under the 505(b)(2) pathway.

 

VTI-001/Brimochol (Visus Therapeutics)

VTI-001, also known as Brimochol, combines two active ingredients: carbachol and brimonidine tartrate. It is the lead investigational medicine candidate being developed by Visus Therapeutics for adults who suffer from presbyopia. The company is investigating the drug as a prescription eye drop designed to correct the loss of near vision associated with presbyopia.

Note: Detailed emerging therapies assessment will be provided in the final report.

Presbyopia Market Outlook

Presbyopia is the gradual reduction in flexibility of the lens of the eye with age. A normal part of aging, presbyopia usually becomes noticeable between the ages of 40 and 50 as an inability to focus on near objects. Patients may experience a noteworthy visual disability if a correction is not made and may also develop problems maintaining the usual levels of activity and productivity at work and everyday activities. The goal of treatment is to compensate for the inability of the eyes to focus on nearby objects. Presbyopia cannot be cured, but properly prescribed glasses or contact lenses can make seeing up close much more comfortable.

 

The pharmacological control of presbyopia is a desirable option for those affected by presbyopia and with an increasing near vision spectacle dependence. Current clinical management of presbyopia in the United States includes off-label treatment using miotic agents, such as pilocarpine and carbachol. Pharmacological treatment of presbyopia is based on using ophthalmic drops, which by the impact on the ciliary muscle, changes the pupil size and elasticity, improving near vision. Many different modifications, including the combination of two parasympathomimetics and an NSAID, two parasympathomimetics and one parasympatholytic, carbachol 2.25% with brimonidine 0.2%, and a combination of pilocarpine 0.247%, phenylephrine 0.78%, polyethylene glycol 0.09%, nepafenac 0.023%, pheniramine 0.034%, and naphazoline 0.003% were studied.

 

At present, some companies have initiated clinical trials that investigate new treatment options. Key players such as Orasis Pharmaceuticals (PresbiDrops), Novartis (UNR844), Eyenovia (MicroLine), Allergan (acquired by AbbVie) (AGN-190584 and AGN-241622), Ocuphire Pharma (Nyxol), Visus therapeutics (VTI-001/Brimochol), and several others are investigating their candidates for the management of presbyopia in the 7MM.

 

Key Findings

The Presbyopia market size in the 7MM is expected to change during the study period 2018–2030. The therapeutic market of Presbyopia in the seven major markets is expected to increase during the study period (2018–2030) with a CAGR of 4%. According to the estimates, the highest market size of Presbyopia is found in the United States followed by Germany.

 

The United States Market Outlook

The total market size of Presbyopia therapies in the United States is expected to increase with a CAGR of 5.6% in the study period (2018–2030).

 

EU-5 Countries: Market Outlook

The total market size of Presbyopia therapies in EU-5 countries is expected to increase with a CAGR of 2.3% in the study period (2018–2030).

 

Japan Market Outlook

The total market size of Presbyopia therapies in Japan is expected to increase with a CAGR of 2.2% in the study period (2018–2030).

Request for sample pages @ Presbyopia Market Size

Table of contents

1. Key Insights

2. Report Introduction

3. Presbyopia Market Overview at a Glance

3.1. Market Share (%) Distribution of Presbyopia in 2018

3.2. Market Share (%) Distribution of Presbyopia in 2030

4. Executive Summary of Presbyopia

5. Presbyopia Market: Future Perspective

6. Epidemiology and Market Methodology

7. Disease Background and Overview

7.1. Introduction

7.1.1. Signs and Symptoms of Presbyopia

7.1.2. Difference between Presbyopia and Hyperopia

7.1.3. Risk Factors and Causes of Presbyopia

7.1.4. Pathophysiology of Presbyopia

7.1.5. Complications of Presbyopia

7.2. Diagnosis of Presbyopia

7.3. Patient History

7.4. Ocular Examination

7.4.1. Visual Acuity

7.4.2. Keratometry/Topography

7.4.3. Refraction

7.4.4. Binocular Vision and Accommodation

7.5. Supplemental Testing

7.6. Eye health evaluation

7.7. Recommended eye examination frequency for pediatric patients and adults

7.8. Differential Diagnosis

8. Early Detection and Prevention of Presbyopia

9. Current Treatment Practices: Presbyopia

9.1. Treatment Algorithm of Presbyopia

9.2. Optical Correction with Spectacle Lenses

9.3. Optical Correction with Contact Lenses

9.4. Surgical options

9.4.1. Conductive keratoplasty (CK)

9.4.2. Monovision LASIK for presbyopia

9.4.3. Laser-Assisted Sub Epithelial Keratectomy (LASEK)

9.4.4. Difference between LASIK and LASEK

9.4.5. Photorefractive keratectomy (PRK)

9.4.6. IntraCor – Corneal Surgery

9.4.7. Multifocal Corneal Ablation

9.5. Corneal inlay

9.6. Lens implants

9.7. Current Pharmacological Treatment

10. Guidelines of Presbyopia

10.1. Management Strategies for Correction of Presbyopia- American Optometric Association

10.1.1. General Considerations

10.1.2. Patient Education

10.1.3. Prognosis and Follow-up

10.2. NICE guidance for corneal inlay implantation for correction of presbyopia

10.3. Management guidelines by the American Academy of Ophthalmology

10.4. Analysis of Guidelines

11. Epidemiology and Patient Population

11.1. Key Findings

11.2. Epidemiology of Presbyopia

11.3. Epidemiology Scenario: 7MM

11.3.1. Total Prevalent Cases of Presbyopia

11.3.2. Total Diagnosed Cases of Presbyopia

11.3.3. Total Age-specific Cases of Presbyopia

11.3.4. Gender-specific Cases of Presbyopia

11.3.5. Severity-specific Cases of Presbyopia

11.3.6. Total Treated Cases of Presbyopia

12. The United States

12.1. Total Prevalent Cases of Presbyopia

12.2. Total Diagnosed Cases of Presbyopia

12.3. Total Age-specific Cases of Presbyopia

12.4. Gender-specific Cases of Presbyopia

12.5. Severity-specific Cases of Presbyopia

12.6. Total Treated Cases of Presbyopia

13. EU-5

13.1. Germany

13.1.1. Total Prevalent Cases of Presbyopia

13.1.2. Total Diagnosed Cases of Presbyopia

13.1.3. Total Age-specific Cases of Presbyopia

13.1.4. Gender-specific Cases of Presbyopia

13.1.5. Severity-specific Cases of Presbyopia

13.1.6. Total Treated Cases of Presbyopia

13.2. France

13.2.1. Total Prevalent Cases of Presbyopia

13.2.2. Total Diagnosed Cases of Presbyopia

13.2.3. Total Age-specific Cases of Presbyopia

13.2.4. Gender-specific Cases of Presbyopia

13.2.5. Severity-specific Cases of Presbyopia

13.2.6. Total Treated Cases of Presbyopia

13.3. Italy

13.3.1. Total Prevalent Cases of Presbyopia

13.3.2. Total Diagnosed Cases of Presbyopia

13.3.3. Total Age-specific Cases of Presbyopia

13.3.4. Gender-specific Cases of Presbyopia

13.3.5. Severity-specific Cases of Presbyopia

13.3.6. Total Treated Cases of Presbyopia

13.4. Spain

13.4.1. Total Prevalent Cases of Presbyopia

13.4.2. Total Diagnosed Cases of Presbyopia

13.4.3. Total Age-specific Cases of Presbyopia

13.4.4. Gender-specific Cases of Presbyopia

13.4.5. Severity-specific Cases of Presbyopia

13.4.6. Total Treated Cases of Presbyopia

13.5. The United Kingdom

13.5.1. Total Prevalent Cases of Presbyopia

13.5.2. Total Diagnosed Cases of Presbyopia

13.5.3. Total Age-specific Cases of Presbyopia

13.5.4. Gender-specific Cases of Presbyopia

13.5.5. Severity-specific Cases of Presbyopia

13.5.6. Total Treated Cases of Presbyopia

14. Japan

14.1. Total Prevalent Cases of Presbyopia

14.2. Total Diagnosed Cases of Presbyopia

14.3. Total Age-specific Cases of Presbyopia

14.4. Gender-specific Cases of Presbyopia

14.5. Severity-specific Cases of Presbyopia

14.6. Total Treated Cases of Presbyopia

15. Patient Journey

16. Key Endpoints in Presbyopia Clinical Trials

17. Emerging Therapies

17.1. AGN-190584: Allergan (acquired by AbbVie)

17.1.1. Product Description

17.1.2. Other Developmental Activities

17.1.3. Clinical Development

17.1.4. Safety and Efficacy

17.2. MicroLine (Pilocarpine Ophthalmic): Eyenovia

17.2.1. Product Description

17.2.2. Other Developmental Activities

17.2.3. Clinical Development

17.3. PresbiDrops (CSF-1): Orasis Pharmaceuticals

17.3.1. Product Description

17.3.2. Other Developmental Activities

17.3.3. Clinical Development

17.3.4. Safety and Efficacy

17.4. Nyxol (Phentolamine Mesylate): Ocuphire Pharma

17.4.1. Product Description

17.4.2. Other Developmental Activities

17.4.3. Clinical Development

17.5. UNR844 (Lipoic acid choline ester; formerly known as EV06): Novartis

17.5.1. Product Description

17.5.2. Other Developmental Activities

17.5.3. Clinical Development

17.5.4. Safety and Efficacy

17.6. VTI-001 (Brimochol): Visus Therapeutics

17.6.1. Product Description

17.6.2. Other Developmental Activities

17.6.3. Clinical Development

17.7. AGN-241622: Allergan (acquired by AbbVie)

17.7.1. Product Description

17.7.2. Clinical Developmental

18. Conjoint Analysis of Presbyopia

19. Presbyopia: 7 Major Market Analysis

19.1. Key Findings

19.2. Market Outlook

19.3. 7MM Market Size

19.3.1. Total Market Size of Presbyopia in the 7MM

19.3.2. Market Size of Presbyopia by Therapies in the 7MM

20. The United States Market Size

20.1. Total Market Size of Presbyopia in the United States

20.2. Market Size of Presbyopia by Therapies in the United States

21. EU-5 Market Size

21.1. Germany

21.1.1. Total Market size of Presbyopia in Germany

21.1.2. Market Size of Presbyopia by Therapies in Germany

21.2. France

21.2.1. Total Market size of Presbyopia in France

21.2.2. Market Size of Presbyopia by Therapies in France

21.3. Italy

21.3.1. Total Market size of Presbyopia in Italy

21.3.2. Market Size of Presbyopia by Therapies in Italy

21.4. Spain

21.4.1. Total Market size of Presbyopia in Spain

21.4.2. Market Size of Presbyopia by Therapies in Spain

21.5. The United Kingdom

21.5.1. Total Market size of Presbyopia in the United Kingdom

21.5.2. Market Size of Presbyopia by Therapies in the United Kingdom

22. Japan

22.1. Total Market size of Presbyopia in Japan

22.2. Market Size of Presbyopia by Therapies in Japan

23. Market Access and Reimbursement

24. KOL Views

25. Market Drivers

26. Market Barriers

27. SWOT Analysis

28. Unmet Needs

29. Appendix

29.1. Bibliography

29.2. Report Methodology

30. DelveInsight Capabilities

31. Disclaimer

32. About DelveInsight

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/